FibroBiologics Receives Canadian Patent for Novel Cachexia Treatment Using Fibroblast Cells

FibroBiologics has been issued a Canadian patent for a novel fibroblast-based treatment for cachexia. The patent covers methods and compositions for treating cachexia through immune-modulating fibroblasts, which suppress inflammation and address the root cause of cachexia. The treatment could potentially restore physiological, immunological, and metabolic homeostasis and prevent weight loss in patients with chronic diseases. This milestone expands the company's global IP protection and brings it closer to delivering transformative therapies for millions of patients worldwide.